Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.
Bonnie Gills
Advertisement
Articles by Bonnie Gills
Treatment of selected cases of localized lymphoma during the second and third trimester was associated with minimal maternal and fetal risk of complications.
Advertisement
Latest Updated Articles
Lymphoma During Pregnancy Can Be Safely ManagedPublished: March 12th 2012 | Updated:
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple MyelomaPublished: March 20th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5